| Patents for A61P 25 - Drugs for disorders of the nervous system (183,225) |
|---|
| 02/13/2003 | WO2003011252A1 Pharmaceutical composition comprising lipids comprising a polar and a nonpolar moiety |
| 02/13/2003 | WO2003011228A2 Purification and crystalline forms of zaleplon |
| 02/13/2003 | WO2003011227A2 Taste masking composition |
| 02/13/2003 | WO2003011220A2 Animal model for fatty acid amide-related neurobehaviors |
| 02/13/2003 | WO2003011219A2 Mediators of hedgehog signaling pathways, compositions and uses related thereto |
| 02/13/2003 | WO2003011210A2 Arylheteroalkylamine derivatives and their use as inhibitors of nitric oxide synthase |
| 02/13/2003 | WO2003004016A8 Use of substituted gamma-lactone compounds as medicaments |
| 02/13/2003 | WO2002096855A3 Anticholinergic compounds and methods of use |
| 02/13/2003 | WO2002088146A3 ANTIDEPRESSANT INDOLETETRAHYDROPYRIDINE DERIVATIVES OF 2,3-DIHYDRO-7H-[1,4]DIOXINO[2,3-e]INDOLE |
| 02/13/2003 | WO2002076995A3 2-amino-propanol derivatives |
| 02/13/2003 | WO2002060427A3 Methods of using and compositions comprising (+) sibutramine optionally in combination with other pharmacologically active compounds |
| 02/13/2003 | WO2002059082A8 Aryl and aminoaryl substituted serotonin receptor agonist and antagonist ligands |
| 02/13/2003 | WO2002055492A3 An improved process for preparing pure ondansetron hydrochloride dihydrate |
| 02/13/2003 | WO2002053556A3 Pyrrolidinylmethyl substituted decahydroisoquinolines as excitatory amino acid receptor antagonists |
| 02/13/2003 | WO2002051434A3 Modulation of smr1-nep interactions in cns disorders giving rise to mental disorders |
| 02/13/2003 | WO2002049667A3 Vaccine for treating nicotine addiction |
| 02/13/2003 | WO2002047719A3 Survical promoting ncam binding and ncam ligand biding compounds |
| 02/13/2003 | WO2002046192A3 Thioether substituted imidazoquinolines |
| 02/13/2003 | WO2002046163A3 Quinoline derivatives and their use as anti-epileptics |
| 02/13/2003 | WO2002041691A3 Transgenic or recombinant non-human mammals and their uses in screening psycho-active medicines |
| 02/13/2003 | WO2002040462A3 Cysteine protease inhibitors |
| 02/13/2003 | WO2002038141A9 Compositions and methods for treatment of mild cognitive impairment |
| 02/13/2003 | WO2002038129A3 Delayed-release pharmaceutical formulations containing proinsulin c-peptide |
| 02/13/2003 | WO2002037927A3 Compounds and methods for promoting smoking cessation |
| 02/13/2003 | WO2002032958A3 Polynucleotide and polypeptide sequences of human dendritic cell immunoreceptors |
| 02/13/2003 | WO2002031115A3 Nucleic acid molecules and polypeptides for immune modulation |
| 02/13/2003 | WO2001087286A3 Antisense enzyme inhibitors for improving pharmacokinetics of a drug |
| 02/13/2003 | US20030033623 Animal model for use in the treatment and diagnosis of nervous system disorders |
| 02/13/2003 | US20030033089 Substituted quinazolines and analogs and the use thereof |
| 02/13/2003 | US20030032995 Thermotherapy via targeted delivery of nanoscale magnetic particles |
| 02/13/2003 | US20030032834 Aminoalcohol derivatives |
| 02/13/2003 | US20030032812 Cyclobutaindolecarboxamide compounds |
| 02/13/2003 | US20030032803 Novel amide derivatives as inhibitors of matrix metalloproteinases, TNF-alpha, and aggrecanase |
| 02/13/2003 | US20030032800 Dibenzo(b,f)azepine derivatives and their preparation |
| 02/13/2003 | US20030032673 Therapeutic strategies for prevention and treatment of alzheimer's disease |
| 02/13/2003 | US20030032670 Monohydrate of cis-lithium-cyano-4-[3-(cyclopentyloxy)-4-methoxyphenyl)cyclohexanecarboxylate |
| 02/13/2003 | US20030032663 Inhibition of the interaction of RAGE with its ligands; treatment acute and chronic inflammation, the development of diabetic late complications, Alzheimer's disease, erectile dysfunction, and tumor invasion and metastasis. |
| 02/13/2003 | US20030032658 Muscarinic receptor agonists |
| 02/13/2003 | US20030032655 Heme oxygenase-1 inducers or induction enhancers |
| 02/13/2003 | US20030032651 Intrathecal analgesia method |
| 02/13/2003 | US20030032648 8-Aza-bicyclo[3.2.1]octan-3-ol derivatives of 2,3-dihydro-1,4-benodioxan as 5-HT1A antagonists |
| 02/13/2003 | US20030032645 Aryl-8-azabicyclo [3.2.1] octanes for the treatment of depression |
| 02/13/2003 | US20030032640 Novel composition |
| 02/13/2003 | US20030032636 For the treatment of depression and other affective disorders. |
| 02/13/2003 | US20030032635 Heterocyclic esters and amides |
| 02/13/2003 | US20030032630 Use of a 2-hydroxy-4-trifluoromethylbenzoic acid derivatives as inhibitors of the activation of the nuclear transcription factor NF-kappaB |
| 02/13/2003 | US20030032626 Substituted naphthyl indole derivatives as inhibitors of plasminogen activator inhibitor type-1 (PAI-1) |
| 02/13/2003 | US20030032579 Therapeutic use of selective PDE10 inhibitors |
| 02/13/2003 | US20030032181 Generation of radial glial cells for use in the treatment of nervous system disorders; obtain neuronal stem cells, incubate with modulator, propagate cells, recover glial cells |
| 02/13/2003 | US20030032179 Post-partum mammalian placenta, its use and placental stem cells therefrom |
| 02/13/2003 | US20030032097 DNA encoding human vanilloid receptor VR3 |
| 02/13/2003 | US20030031712 Opioid agonist /antagonist combinations |
| 02/13/2003 | US20030031706 Carotenoid formulations, comprising a mixture of beta-carotene, lycopene and lutein |
| 02/13/2003 | CA2493888A1 Natural marine source phospholipids comprising flavonoids, polyunsaturated fatty acids and their applications |
| 02/13/2003 | CA2457100A1 Taste masking composition |
| 02/13/2003 | CA2456192A1 Pyrazole-derived kinase inhibitors and uses thereof |
| 02/13/2003 | CA2456187A1 Pyrazole-derived kinase inhibitors and uses thereof |
| 02/13/2003 | CA2456004A1 Process for the preparation of 5-substituted isobenzofurans |
| 02/13/2003 | CA2456003A1 Regulator of calcineurin |
| 02/13/2003 | CA2455969A1 Methods for inhibiting or reversing tau filament formation polymerization |
| 02/13/2003 | CA2455963A1 Glp-1 exendin-4 peptide analogs and uses thereof |
| 02/13/2003 | CA2455833A1 1,3,5-triazine-2,4,6-triones, preparation and use as gonadotropin-releasing hormone receptor antagonists |
| 02/13/2003 | CA2455772A1 Substituted isoindoles and their use |
| 02/13/2003 | CA2455753A1 Novel 2,4-diaminothiazole derivatives |
| 02/13/2003 | CA2455711A1 As-needed administration of orally active androgenic agents to enhance female sexual desire and responsiveness |
| 02/13/2003 | CA2455555A1 Animal model for fatty acid amide-related neurobehaviors |
| 02/13/2003 | CA2455398A1 Use of peptide fragments of the calcium channel .alpha.-1 subunit, optionally comprising mutations, for screening molecules of therapeutic interest |
| 02/13/2003 | CA2455235A1 1,2,4-triazin-3,5-diones as gonadotropin-releasing hormone receptor (gnrh) antagonists |
| 02/13/2003 | CA2455100A1 Mediators of hedgehog signaling pathways,compositions and uses related thereto |
| 02/13/2003 | CA2454937A1 Modulators of notch signalling for use in immunotherapy |
| 02/13/2003 | CA2454935A1 Method for the nitration of phenolic compounds |
| 02/13/2003 | CA2454414A1 Use of 2-alkoxyphenyl-substituted imidazotriazinones |
| 02/13/2003 | CA2453751A1 Purification and crystalline forms of zapelon |
| 02/13/2003 | CA2453274A1 Thienopyrimidinediones and their use in the modulation of autoimmune disease |
| 02/13/2003 | CA2452743A1 5-arylsulfonyl indoles having 5-ht6 receptor affinity |
| 02/13/2003 | CA2452665A1 Novel vinyl carboxylic acid derivatives and their use as antidiabetics etc. |
| 02/13/2003 | CA2452524A1 Use of lhrh-antagonists for the improvement of t-cell mediated immunity |
| 02/13/2003 | CA2452347A1 Treatment of chronic pain with 3-aryloxy-3-phenylpropanamines |
| 02/13/2003 | CA2451868A1 Pharmaceutical composition comprising lipids comprising a polar and a nonpolar moiety |
| 02/13/2003 | CA2451288A1 Treatment of chronic pain with 3-heterocyclyl- and 3-cycloalkyl-3-aryloxypropanamines |
| 02/13/2003 | CA2417337A1 Novel crystal forms of 9-substituted hypoxanthine derivatives |
| 02/12/2003 | EP1283260A1 Novel insulin/igf/relaxin family polypeptides and dnas thereof |
| 02/12/2003 | EP1283203A1 Crystalline form of 4-(5-methyl-3-phenylisoxazol-4-yl) benzene-sulfonamide |
| 02/12/2003 | EP1283057A1 Cell proliferation inhibitors |
| 02/12/2003 | EP1283055A1 Soluble beta amyloid precursor protein secretion promoters |
| 02/12/2003 | EP1283054A1 Drugs for complications of diabetes and neuropathy and utilization thereof |
| 02/12/2003 | EP1283047A1 Method for producing a bioactive substance from blood serum |
| 02/12/2003 | EP1283039A1 -secretase inhibitors |
| 02/12/2003 | EP1283038A1 Compositions normalizing circadian rhythm |
| 02/12/2003 | EP1283037A1 Remedies |
| 02/12/2003 | EP1282703A2 Rabies virus-specific neutralizing human monoclonal antibodies and nucleic acids and related methods |
| 02/12/2003 | EP1282700A1 Neuronal serine-threonine protein kinase |
| 02/12/2003 | EP1282643A2 Anti-inflammatory compounds and uses thereof |
| 02/12/2003 | EP1282636A2 Trp8, a transient receptor potential channel expressed in taste receptor cells |
| 02/12/2003 | EP1282626A2 Polyketide derivatives |
| 02/12/2003 | EP1282625A1 Benzoxazines for use in the treatment of parkinson's disease |
| 02/12/2003 | EP1282624A1 Crf receptor antagonists and methods relating thereto |
| 02/12/2003 | EP1282623A1 Pyrazolo-triazine derivatives as ligands for gaba receptors |
| 02/12/2003 | EP1282622A1 Crf receptor antagonists and methods relating thereto |
| 02/12/2003 | EP1282620A1 Azabicyclic carbamates and their use as alpha-7 nicotinic acetylcholine receptor agonists |